CorMedix Inc (CRMD)

Sep 27, 2026

CorMedix (CRMD) has shown significant growth in revenue, driven by DefenCath and the acquisition of Melinta, and possesses strong liquidity. However, its earnings visibility is limited due to upcoming changes in DefenCath reimbursement and increased operating costs as the company expands and integrates new acquisitions. While the company has commercial traction, a "Hold" rating is suggested as it navigates these challenges.

Sep 23, 2026

Oppenheimer has initiated coverage on CorMedix (NASDAQ:CRMD) with an "outperform" rating and a $15 price target, suggesting a significant upside of 92.80% from its current price. This aligns with a "Moderate Buy" consensus from other analysts, with seven rating it Buy and two Hold. The biopharmaceutical company also recently surpassed quarterly earnings expectations, reporting higher EPS and revenue than forecast, and institutional investors hold a substantial stake in the company.

Sep 19, 2026

CorMedix Inc. (CRMD) shows a promising 97.69% potential upside according to analyst ratings, driven by its flagship product DefenCath and strong revenue growth of 156.50%. Despite its relatively small market cap, the biotech company is focused on combating catheter-related bloodstream infections in kidney dialysis patients. While current technical indicators suggest a mixed short-term outlook, a bullish analyst consensus with an average target price of $15.40 highlights strong confidence in CorMedix's future.